- Current report filing (8-K)
October 30 2008 - 2:49PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 27,
2008
ARNO
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
000-52153
|
52-2286452
|
(Commission
File Number)
|
(IRS
Employer
|
|
Identification
No.)
|
30
Two Bridges Rd., Suite #270
Fairfield,
NJ 07004
(Address
of principal executive offices and Zip Code)
(862)
703-7170
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K is intended to simultaneously satisfy
the
filing obligation of the registrant under any of the following
provisions:
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-14(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 5.02.
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment
of
Certain Officers; Compensatory Arrangements of Certain Officers.
|
On
October 27, 2008, William F. Hamilton, Ph.D. was appointed to serve as a member
of the board of directors of Arno Therapeutics, Inc. (the “Company”). Dr.
Hamilton was also appointed to serve as chairman of the Company’s audit
committee.
Dr.
Hamilton, age 69, has served on the University of Pennsylvania faculty since
1967, and is the Landau Professor of Management and Technology, and Director
of
the Jerome Fisher Program in Management and Technology at The Wharton School
and
the School of Engineering and Applied Science. He serves as a director of Neose
Technologies, Inc. and NovaDel Pharma Inc., both publicly-traded biotechnology
companies. Dr. Hamilton also serves on the boards of directors of Yaupon
Therapeutics, Inc., a privately-held specialty pharmaceutical company that
develops small molecule pharmaceuticals licensed from academic laboratories,
Avid Radiopharmaceuticals, Inc., a privately-held clinical-stage product-focused
molecular imaging company and Neuro Diagnostic Devices Inc., a privately-held
development-stage medical device company. Dr. Hamilton received his B.S. and
M.S. in chemical engineering and his MBA from the University of Pennsylvania,
and his Ph.D. in applied economics from the London School of
Economics.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
October 30, 2008
|
|
|
|
Arno
Therapeutics, Inc.
|
|
|
|
|
By:
|
/s/ Brian
Lenz
|
|
Brian
Lenz
|
|
Chief
Financial Officer
|
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024